Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will host a conference call on Thursday, September 29, 2016 at 12:00 p.m. Eastern Time (6:00 p.m. Central European Time) to discuss top-line results from the recently completed Phase IIa clinical trial of lead drug candidate QGC001, in hypertension.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/09/QUANTUM_PR_QGC001-Webcast_2016092_VDEF_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
